1-18 of 18
Andrew J. Wagner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

J. Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik, Mrinal Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás-Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros-Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan, Ariel Lefkovith, Scott Innis, Alexander J. Lazar, Gregory M. Cote, Andrew J. Wagner
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-2583
Published: 16 January 2025
View article titled, A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
Open the PDF for A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors in another window
Includes: Supplementary data
Journal Articles

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Hans Gelderblom, Albiruni A. Razak, Matthew H. Taylor, Todd M. Bauer, Breelyn Wilky, Javier Martin-Broto, Alejandro F. Gonzalez, Piotr Rutkowski, Bartlomiej Szostakowski, Thierry Alcindor, Ramy Saleh, Sofia Genta, Silvia Stacchiotti, Michiel van de Sande, Andrew J. Wagner, Nicholas Bernthal, Lara E. Davis, Jacqueline Vuky, Christopher Tait, Bahar Matin, Supraja Narasimhan, Maitreyi G. Sharma, Rodrigo Ruiz-Soto, Matthew L. Sherman, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 3996–4004.
https://doi.org/10.1158/1078-0432.CCR-24-0103
Published: 13 September 2024
View article titled, CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Open the PDF for CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma

Gregory M. Cote, Candace L. Haddox, Edwin Choy, Priscilla A. Merriam, Emanuele Mazzola, Vinayak Venkataraman, Thierry Alcindor, Andrew J. Wagner, George D. Demetri, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (13): 2702–2708.
https://doi.org/10.1158/1078-0432.CCR-24-1037
Published: 01 July 2024
View article titled, Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma
Open the PDF for Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma in another window
Includes: Supplementary data
Journal Articles

Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal, Philip J. Ebert, Andrew J. Wagner, Jennifer Wright, Javier Martin-Broto, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2598–2608.
https://doi.org/10.1158/1078-0432.CCR-23-3936
Published: 03 June 2024
View article titled, Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Open the PDF for Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

Candace L. Haddox, Michael J. Nathenson, Emanuele Mazzola, Jia-Ren Lin, Joanna Baginska, Allison Nau, Jason L. Weirather, Edwin Choy, Adrian Marino-Enriquez, Jeffrey A. Morgan, Gregory M. Cote, Priscilla Merriam, Andrew J. Wagner, Peter K. Sorger, Sandro Santagata, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1281–1292.
https://doi.org/10.1158/1078-0432.CCR-23-2250
Published: 01 April 2024
View article titled, Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
Open the PDF for Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates in another window
Includes: Supplementary data
Journal Articles

Abstract B010: Response to treatment with nab-sirolimus among patients with primary uterine tumors: A subgroup analysis from AMPECT

Vinod Ravi, Mark A. Dickson, Kristin Ganjoo, Li Ding, Anita N. Schmid, Norma A. Palma, Willis H. Navarro, Andrew J. Wagner
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5_Supplement): B010.
https://doi.org/10.1158/1557-3265.ENDO24-B010
Published: 01 March 2024
View article titled, Abstract B010: Response to treatment with <em>nab</em>-sirolimus among patients with primary uterine tumors: A subgroup analysis from AMPECT
Journal Articles

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

Patrick Schöffski, Rastislav Bahleda, Andrew J. Wagner, Melissa A. Burgess, Niels Junker, Michael Chisamore, Patrick Peterson, Anna M. Szpurka, Matteo Ceccarelli, William D. Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3320–3328.
https://doi.org/10.1158/1078-0432.CCR-23-0742
Published: 01 September 2023
View article titled, Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Open the PDF for Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma in another window
Includes: Supplementary data
Journal Articles

Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma

Andrew J. Wagner, Gregory M. Cote, Donald Richards, Nicholas J. Vogelzang, William J. Edenfield, Mitchell E. Gross, Lynn Mar, Gil D. Fine, Edward Dow, John A. Charlson
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A019.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A019
Published: 15 September 2022
View article titled, Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma
Journal Articles

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

William D. Tap, Arun S. Singh, Stephen Patrick Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Zev A. Wainberg, Igor Puzanov, Gregory M. Cote, Andrew J. Wagner, Fadi Braiteh, Eric Sherman, Henry H. Hsu, Charles Peterfy, Heather L. Gelhorn, Xin Ye, Paul Severson, Brian L. West, Paul S. Lin, Sandra Tong-Starksen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 298–307.
https://doi.org/10.1158/1078-0432.CCR-21-2007
Published: 15 January 2022
View article titled, Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Open the PDF for Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT in another window
Includes: Supplementary data
Journal Articles

Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial

Robin L. Jones, Andrew J. Wagner, Akira Kawai, Kazuo Tamura, Ashwin Shahir, Brian A. Van Tine, Javier Martín-Broto, Patrick M. Peterson, Jennifer Wright, William D. Tap
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (14): 3861–3866.
https://doi.org/10.1158/1078-0432.CCR-20-4592
Published: 15 July 2021
View article titled, Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial
Open the PDF for Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

César Serrano, Alessandro Leal, Yanan Kuang, Jeffrey A. Morgan, Constance M. Barysauskas, Jillian Phallen, Olivia Triplett, Adrián Mariño-Enríquez, Andrew J. Wagner, George D. Demetri, Victor E. Velculescu, Cloud P. Paweletz, Jonathan A. Fletcher, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7287–7293.
https://doi.org/10.1158/1078-0432.CCR-19-2150
Published: 13 December 2019
View article titled, Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Open the PDF for Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors in another window
Includes: Supplementary data
Journal Articles

Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma

Ali Amin-Mansour, Suzanne George, Stefano Sioletic, Scott L. Carter, Mara Rosenberg, Amaro Taylor-Weiner, Chip Stewart, Aaron Chevalier, Sara Seepo, Adam Tracy, Gad Getz, Jason L. Hornick, Marisa R. Nucci, Bradley Quade, George D. Demetri, Chandrajit P. Raut, Levi A. Garraway, Eliezer M. Van Allen, Andrew J. Wagner
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 5135–5142.
https://doi.org/10.1158/1078-0432.CCR-19-0271
Published: 15 August 2019
View article titled, Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Open the PDF for Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Saoirse O. Dolly, Andrew J. Wagner, Johanna C. Bendell, Hedy L. Kindler, Lee M. Krug, Tanguy Y. Seiwert, Marjorie G. Zauderer, Martijn P. Lolkema, Doris Apt, Ru-Fang Yeh, Jill O. Fredrickson, Jill M. Spoerke, Hartmut Koeppen, Joseph A. Ware, Jennifer O. Lauchle, Howard A. Burris, 3rd, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2874–2884.
https://doi.org/10.1158/1078-0432.CCR-15-2225
Published: 14 June 2016
View article titled, Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines

John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allsop, Catia Fonseca, Yukoh Nakazaki, David Nemer, Chandrajit P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, Glenn Dranoff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3178–3186.
https://doi.org/10.1158/1078-0432.CCR-14-2932
Published: 14 July 2015
View article titled, Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines
Open the PDF for Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines in another window
Journal Articles

A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors

Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, Anthony B. El-Khoueiry
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (5): 1044–1051.
https://doi.org/10.1158/1078-0432.CCR-14-1116
Published: 01 March 2015
View article titled, A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, George D. Demetri
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (21): 6020–6029.
https://doi.org/10.1158/1078-0432.CCR-13-0953
Published: 31 October 2013
View article titled, A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas
Open the PDF for A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy

Yi-Xiang Zhang, Jolieke G. van Oosterwijk, Ewa Sicinska, Samuel Moss, Stephen P. Remillard, Tom van Wezel, Claudia Bühnemann, Andrew B. Hassan, George D. Demetri, Judith V.M.G. Bovée, Andrew J. Wagner
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (14): 3796–3807.
https://doi.org/10.1158/1078-0432.CCR-12-3647
Published: 15 July 2013
View article titled, Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy
Open the PDF for Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy in another window
Includes: Supplementary data
Journal Articles

Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

Richard Quek, Qian Wang, Jeffrey A. Morgan, Geoffrey I. Shapiro, James E. Butrynski, Nikhil Ramaiya, Tarsha Huftalen, Nicole Jederlinic, Judith Manola, Andrew J. Wagner, George D. Demetri, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 871–879.
https://doi.org/10.1158/1078-0432.CCR-10-2621
Published: 15 February 2011
View article titled, Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
Open the PDF for Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors in another window